A5061059143- Eating Disorders and Behaviors
- Autism Spectrum Disorder Research
- Neuroendocrine regulation and behavior
- Psychedelics and Drug Studies
- Neurotransmitter Receptor Influence on Behavior
- Obsessive-Compulsive Spectrum Disorders
- Genetics and Neurodevelopmental Disorders
- Cannabis and Cannabinoid Research
- Neurological disorders and treatments
- Tryptophan and brain disorders
- Diet and metabolism studies
Monash University
2022-2024
Australian Regenerative Medicine Institute
2022-2024
Discovery Institute
2023
Abstract Psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials the treatment anorexia nervosa (AN), a condition that characterised by persistent cognitive inflexibility. Considering enhanced flexibility after psilocybin reported to occur individuals with depression, it plausible could improve AN breaking down A mechanistic understanding actions required tailor application most likely respond positive outcomes. This can only be achieved using...
Anorexia nervosa (AN) is a complex psychiatric disorder characterised by severe pathological weight loss and persistent cognitive inflexibility. Converging evidence from neuroimaging studies genome-wide association study (GWAS) suggests the involvement of prefrontal cortex (PFC) striatum dysfunction in pathophysiology AN. However, identifying causal role circuit-specific genes development AN-like phenotype remains challenging requires combination novel molecular tools preclinical models. The...
Anorexia nervosa has among the highest mortality rates of any psychiatric disorder and is characterized by cognitive inflexibility that persists after weight recovery contributes to chronic nature condition. What remains unknown whether predisposes individuals anorexia nervosa, a question difficult address in human studies. Our previous work using most well-established animal model known as activity-based (ABA) identified neurobiological link between susceptibility pathological loss female...
Abstract Psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials the treatment anorexia nervosa (AN), a condition that characterised by persistent cognitive inflexibility. Considering enhanced flexibility after psilocybin reported to occur individuals with depression, it plausible could improve AN breaking down A mechanistic understanding actions required tailor application most likely respond positive outcomes. This can only be achieved using...
Abstract Anorexia nervosa (AN) has among the highest mortality rates of any psychiatric disorder and is characterised by cognitive inflexibility that persists after weight recovery contributes to low recovery. What remains unknown whether predisposes individuals AN, a question difficult determine from human studies. Our previous work using most well-established animal model known as activity-based anorexia (ABA) identified neurobiological link between susceptibility pathological loss in...